Fulcrum Therapeutics (FULC) Non Operating Income (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Non Operating Income of $3.1 million for Q2 2026, up 24.3% year-over-year from $2.5 million in Q2 2025, and down 4.98% quarter-over-quarter from $3.3 million in Q1 2026.
Fulcrum Therapeutics (FULC) Non Operating Income (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Non Operating Income for 9 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income rose 24.3% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $11.0 million (down 4.41% YoY), while the FY2025 annual figure was $9.9 million, down 18.76% from the prior year.
- Non Operating Income slipped to $3.1 million in Q2 2026 per FULC's latest filing, from $3.3 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.5 million in Q2 2023 and bottomed at $70000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $2.5 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 4415.71% — and 2025, when it tumbled 34.02%.
- Fulcrum Therapeutics' Non Operating Income stood at $1.8 million in 2022, then surged by 76.06% to $3.2 million in 2023, then retreated by 11.59% to $2.9 million in 2024, then decreased by 17.55% to $2.4 million in 2025, then surged by 32.73% to $3.1 million in 2026.
- Business Quant data shows FULC's Non Operating Income at $3.1 million in Q2 2026, $3.3 million in Q1 2026, and $2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 3.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.13 Mn |
| Mar 31, 2026 | 3.30 Mn |
| Dec 31, 2025 | 2.36 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 2.75 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 3.43 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 2.96 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.42 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 617,000.00 |
| Jun 30, 2022 | 165,000.00 |
| Mar 31, 2022 | 70,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 54,000.00 |